3Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys,2000,47:1261-1266.
4Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys,1997,39:347-353.
5Molloy JA, Williams MB. Treatment planning considerations and quality assurance for CT-guided transischiorectal implantation of the prostate. Med Phys,1999,26:1943-1951.
6Martinez-Monge R, Nag S, Nieroda CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer,1999,85:1218-1225.
7Vikram B, Mishra S.Permanent iodine-125 implants in postoperative radiotherapy for head and neck cancer with positive surgical margins. Head Neck,1994,16:155-157.
8Kumar PP, Patil AA, Leibrock LG,et al. Continuous low dose rate brachytherapy with high activity iodine-125 seeds in the management of meningiomas. Int J Radiat Oncol Biol Phys,1993,25:325-328.
9Lee DJ, Liberman FZ, Park RI, et al. Intraoperative I-125 seed implantation for extensive recurrent head and neck carcinomas. Radiology,1991,178:879-882.
10Heelan RT, Hilaris BS, Anderson LL, et al. Lung tumors: percutaneous implantation of I-125 sources with CT treatment planning. Radiology, 1987,164:735-740.
